Key Points:
- Altria has halted sales of its NJOY Ace e-cigarette due to a patent dispute.
- The patent dispute involving NJOY Ace is related to Juul Labs.
- This move is impacting the market, especially the only mint-flavored e-cigarette product authorized for sale.
According to a report from Morningstar on April 2nd, Altria Group has decided to stop selling its NJOY Ace e-cigarette product following a patent dispute with competitor Juul Labs. However, consumers can still purchase the product until the existing inventory at retailers is sold out.
This ruling is a setback for Altria. In 2023, the company had just completed its investment in Juul and agreed to acquire NJOY for at least $2.75 billion. Shortly after, Juul filed a complaint with the U.S. International Trade Commission (ITC), accusing NJOY Ace of patent infringement. The ITC requested that Altria cease importing, distributing, and marketing these devices by March 31. As a result, Altria's stock dropped by about 2% during Tuesday's midday trading.
Among the NJOY products that have been removed from the market is the mint-flavored e-cigarette product that was the only one authorized for sale by the Food and Drug Administration (FDA) in the United States. Altria CEO Billy Gifford stated in a January conference call with analysts that the ITC's decision limits consumer choice and "undermines public health" in a market saturated with illegal products.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
